BLA Accepted and Priority Review Granted for Ocriplasmin for Symptomatic Vitreomacular Adhesion
ThromboGenics announced that the FDA has accepted for filing its Biologics License Application (BLA) for ocriplasmin intravitreal injection 2.5mg/mL and granted it priority review for the treatment of symptomatic Vitreomacular Adhesion (VMA) including macular hole.
Ocriplasmin has successfully completed two Phase 3 clinical trials for the pharmacological treatment of symptomatic VMA, otherwise termed Vitreomacular Traction (VMT), including when associated with macular hole.
Ocriplasmin (microplasmin) is a truncated form of the human serine protease plasmin that retains its enzymatic properties and is believed to primarily target the fibronectin, laminin, and type IV collagen fibers that adhere the vitreous to the retina.
For more information call (212) 201-0920 or visit www.thrombogenics.com.